The Programmers Approach to Real World Data and Using Real World Evidence in Research and Healthcare

by MMS Holdings and MichBio.org

This webinar is intended to help guide individuals towards a better understanding of core concepts and requirements for using real-world data (RWD). Here, we will delve into how one can derive and utilize real-world evidence (RWE) in drug development, from the perspective of a clinical trial programmer/data analyst. We will discuss the potential opportunities that can generate RWD to improve the safety, efficiency, and quality in a clinical paradigm. The knowledge shared in this presentation echoes the regulatory guidance’s for use of RWE. Evolving standards that are necessary to make the most out of RWD, demonstration projects, and first-hand experience with some technical tools will be discussed. Combining it all together should provide the tools and knowledge to navigate more confidently through this less explored, but complex landscape of RWD and RWE.

Speakers include:

  • Narasimha Ayyalas, Manager, Statistical Programming, MMS Holdings
  • Aditya Gadiko, Senior Clinical Programmer, MMS Holdings
  • Susheel Arkala, Manager, Statistical Programming, MMS Holdings
  • Chris Hurley, Associate Director, Data Sciences, MMS Holdings
  • Ravi Yandamuri, Principal Clinical Programmer, MMS Holdings

Suggested For You

perspectives

May 13th, 2026

Beyond Data Cleaning: A Strategic Shift for Clinical Data Management under ICH E6 (R3)

perspectives

May 5th, 2026

A Statistician's Reflection: FDA Guidance on Limiting Crossover in Oncology Studies 

perspectives

April 27th, 2026

From Stigma to Signal: The Executive Order, CNPV Vouchers, and What Comes Next for Psychedelics

perspectives

April 20th, 2026

The FDA Drug Shortage List Signals Deeper Concerns for the US Medicine Supply Chain

perspectives

April 15th, 2026

Decision-Making in Early-Phase Oncology Trials: Navigating Uncertainty with Evidence Frameworks

perspectives

April 8th, 2026

Four Pillars of My Success as a Clinical Trial Transparency Specialist

perspectives

March 25th, 2026

REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons

perspectives

March 12th, 2026

AI in Pharma: Autopilot Is Not the Same as Removing the Pilot 

perspectives

March 3rd, 2026

Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design

perspectives

February 25th, 2026

Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency

perspectives

February 10th, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development